Caxton Associates (New York)’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $1.34M | Sell |
7,566
-6,788
| -47% | -$1.21M | 0.04% | 167 |
|
|
2024
Q3 | $2.83M | Buy |
14,354
+4,141
| +41% | +$818K | 0.11% | 71 |
|
|
2024
Q2 | $1.75M | Sell |
10,213
-13,425
| -57% | -$2.3M | 0.06% | 163 |
|
|
2024
Q1 | $4.3M | Sell |
23,638
-4,360
| -16% | -$794K | 0.24% | 45 |
|
|
2023
Q4 | $4.34M | Buy |
27,998
+10,466
| +60% | +$1.62M | 0.22% | 64 |
|
|
2023
Q3 | $2.61M | Buy |
17,532
+276
| +2% | +$41.1K | 0.36% | 48 |
|
|
2023
Q2 | $2.32M | Buy |
+17,256
| New | +$2.32M | 0.34% | 49 |
|
|
2022
Q4 | – | Sell |
-2,802
| Closed | -$376K | – | 414 |
|
|
2022
Q3 | $376K | Buy |
+2,802
| New | +$376K | 0.05% | 272 |
|
|
2020
Q3 | – | Sell |
-5,500
| Closed | -$540K | – | 280 |
|
|
2020
Q2 | $540K | Buy |
+5,500
| New | +$540K | 0.05% | 107 |
|
|
2020
Q1 | – | Sell |
-6,539
| Closed | -$571K | – | 389 |
|
|
2019
Q4 | $571K | Buy |
+6,539
| New | +$571K | 0.08% | 143 |
|
|
2019
Q3 | – | Sell |
-16,010
| Closed | -$1.16M | – | 369 |
|
|
2019
Q2 | $1.16M | Buy |
+16,010
| New | +$1.16M | 0.14% | 62 |
|
|
2018
Q4 | – | Sell |
-2,887
| Closed | -$273K | – | 259 |
|
|
2018
Q3 | $273K | Sell |
2,887
-5,970
| -67% | -$565K | 0.02% | 290 |
|
|
2018
Q2 | $821K | Sell |
8,857
-332
| -4% | -$30.8K | 0.04% | 153 |
|
|
2018
Q1 | $870K | Buy |
+9,189
| New | +$870K | 0.04% | 163 |
|
|
2017
Q2 | – | Sell |
-7,100
| Closed | -$463K | – | 404 |
|
|
2017
Q1 | $463K | Buy |
+7,100
| New | +$463K | ﹤0.01% | 217 |
|